Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NurExone BiologicNRXBF +29.49%12 PB Ratio is 22.25 as of Jul. 15, 2026. GuruFocus rates NRXBF with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 1,228 Biotechnology companies, NurExone Biologic ranks worse than 92.92% on this metric.
The historical rank and industry rank for NurExone Biologic's PB Ratio or its related term are showing as below:
NRXBF'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 24.48
Current: 24.48
During the past 5 years, NurExone Biologic's highest PB Ratio was 24.48. The lowest was 0.00. And the median was 0.00.
NRXBF's PB Ratio is ranked worse than 92.92% of 1228
companies
in the Biotechnology industry
Industry Median: 2.895
vs NRXBF: 24.48
During the past 12 months, NurExone Biologic's average Book Value Per Share Growth Rate was 20.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -14.00% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of NurExone Biologic was -0.90% per year. The lowest was -14.00% per year. And the median was -7.45% per year.
Back to Basics: PB Ratio
NurExone Biologic (OTCPK:NRXBF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
NurExone Biologic PB Ratio Related Terms
NurExone Biologic PB Ratio Historical Data
* Premium members only.
The historical data trend for NurExone Biologic's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, NurExone Biologic's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NurExone Biologic PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NurExone Biologic's PB Ratio distribution charts can be found below:
* The bar in red indicates where NurExone Biologic's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
NurExone Biologic (NRXBF) has a PB Ratio of 22.25 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on NurExone Biologic and its competitors. According to the industry distribution chart, NurExone Biologic ranks #1141 out of 1228 companies in the Biotechnology industry, placing it in the top 92.9%.
Is NurExone Biologic's PB Ratio too high?
NurExone Biologic's current PB Ratio is 22.25. The Biotechnology industry median PB Ratio is 2.90. NurExone Biologic's value of 22.25 is 668.6% above this industry median. Based on the distribution chart, NurExone Biologic ranks #1141 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NurExone Biologic has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does NurExone Biologic's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, NurExone Biologic ranks #1141 out of 1228 companies for PB Ratio. This places NurExone Biologic in the lower half of its industry. The industry median PB Ratio is 2.90. NurExone Biologic's value of 22.25 is 668.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.90, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NurExone Biologic's current PB Ratio of 22.25 is 668.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on NurExone Biologic and its competitors. For the Biotechnology industry, the median PB Ratio is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NurExone Biologic's current PB Ratio is 22.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NurExone Biologic stock overvalued right now?
NurExone Biologic (NRXBF) has a current PB Ratio of 22.25. The current PB Ratio is 22.25 and 668.6% above the Biotechnology industry median of 2.90. NurExone Biologic's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For NurExone Biologic (NRXBF), the current PB Ratio is 22.25 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Its primary product is ExoTherapy, which is an exosome therapy production platform. It is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). It also aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.
12GF Score
Get the complete analysis for NRXBF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NRXBF has been successfully added to your 
